Trial · NCT02926937
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 (Sotagliflozin 400 mg Versus Placebo) | Placebo | -0.34 | Standard Error 0.120 | percentage of HbA1c | |
| Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 (Sotagliflozin 400 mg Versus Placebo) | Sotagliflozin 400 mg | -1.03 | Standard Error 0.122 | percentage of HbA1c | |
| Change From Baseline in 2-hour Postprandial Plasma Glucose (PPG) Following a Mixed Meal at Week 26 (Sotagliflozin 400 mg Versus Placebo) | Placebo | -0.591 | Standard Error 0.1943 | millimole per liter (mmol/L) | |
| Change From Baseline in 2-hour Postprandial Plasma Glucose (PPG) Following a Mixed Meal at Week 26 (Sotagliflozin 400 mg Versus Placebo) | Sotagliflozin 400 mg | -1.156 | Standard Error 0.1964 | millimole per liter (mmol/L) | |
| Change From Baseline in 2-hour Postprandial Plasma Glucose (PPG) Following a Mixed Meal at Week 26 (Sotagliflozin 200 mg Versus Placebo) | Placebo | -0.500 | Standard Error 0.2443 | mmol/L | |
| Change From Baseline in 2-hour Postprandial Plasma Glucose (PPG) Following a Mixed Meal at Week 26 (Sotagliflozin 200 mg Versus Placebo) | Sotagliflozin 200 mg | -0.847 | Standard Error 0.2477 | mmol/L | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 (Sotagliflozin 400 mg Versus Placebo) | Placebo | -0.201 | Standard Error 0.2739 | mmol/L | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 (Sotagliflozin 400 mg Versus Placebo) | Sotagliflozin 400 mg | -1.756 | Standard Error 0.2719 | mmol/L | |
| Change From Baseline in Systolic Blood Pressure (SBP) at Week 12 in Participants With Baseline SBP ≥130 Millimeter of Mercury (mmHg) (Sotagliflozin 400 mg Versus Placebo) | Placebo | -4.45 | Standard Error 2.419 | mmHg | |
| Change From Baseline in Systolic Blood Pressure (SBP) at Week 12 in Participants With Baseline SBP ≥130 Millimeter of Mercury (mmHg) (Sotagliflozin 400 mg Versus Placebo) | Sotagliflozin 400 mg | -7.96 | Standard Error 2.282 | mmHg | |
| Change From Baseline in SBP at Week 12 for All Participants (Sotagliflozin 400 mg Versus Placebo) | Placebo | -0.57 | Standard Error 1.088 | mmHg | |
| Change From Baseline in SBP at Week 12 for All Participants (Sotagliflozin 400 mg Versus Placebo) | Sotagliflozin 400 mg | -1.35 | Standard Error 1.116 | mmHg | |
| Change From Baseline in SBP at Week 12 for All Participants (Sotagliflozin 200 mg Versus Placebo) | Placebo | -1.62 | Standard Error 1.215 | mmHg | |
| Change From Baseline in SBP at Week 12 for All Participants (Sotagliflozin 200 mg Versus Placebo) | Sotagliflozin 200 mg | -4.82 | Standard Error 1.211 | mmHg | |
| Change From Baseline in Body Weight at Week 26 (Sotagliflozin 400 mg Versus Placebo) | Placebo | -0.79 | Standard Error 0.373 | kilogram (Kg) | |
| Change From Baseline in Body Weight at Week 26 (Sotagliflozin 400 mg Versus Placebo) | Sotagliflozin 400 mg | -2.33 | Standard Error 0.379 | kilogram (Kg) | |
| Change From Baseline in Body Weight at Week 26 (Sotagliflozin 200 mg Versus Placebo) | Placebo | -0.52 | Standard Error 0.509 | kg | |
| Change From Baseline in Body Weight at Week 26 (Sotagliflozin 200 mg Versus Placebo) | Sotagliflozin 200 mg | -1.69 | Standard Error 0.518 | kg | |
| Percentage of Participants With HbA1c <6.5% at Week 26 (Sotagliflozin 400 mg Versus Placebo) | Placebo | 10.7 | percentage of participants | ||
| Percentage of Participants With HbA1c <6.5% at Week 26 (Sotagliflozin 400 mg Versus Placebo) | Sotagliflozin 400 mg | 23.2 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02926937/results